Ali Behbahani
Sits on 7 boards. Overboarded · 7 public boards Last updated September 28, 2026
Time on boards
- Boards served
- 7
- Current seats
- 7
- Board service
- 21 years
- Director since
- 2023
21 years of board service in total across 7 boards, counting each seat separately. Longest: Black Diamond Therapeutics Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Nkarta Inc. June 10, 202668.9%
-
CRISPR Therapeutics AG June 4, 202672.9%
-
Black Diamond Therapeutics Inc. June 12, 202542.1%
-
CRISPR Therapeutics AG June 5, 202572.5%
-
Monte Rosa Therapeutics Inc. June 12, 202460.2%
-
Korro Bio Inc. June 11, 202471.4%
-
CRISPR Therapeutics AG May 30, 202465.7%
-
Nkarta Inc. June 9, 202368.2%
-
CRISPR Therapeutics AG June 8, 202355.3%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 18, 2026 | Black Diamond Therapeutics Inc. | Grant or award | +7,707 | $1.93 | $14,875 |
| Sep 17, 2026 | CRISPR Therapeutics AG | Option exercise | +30,000 | $14.00 | $420,000 |
| Sep 17, 2026 | CRISPR Therapeutics AG | Open-market sale | −13,679 | $57.09 | $780,934 |
| Jul 1, 2026 | Monte Rosa Therapeutics Inc. | Other | −1,000,000 | — | — |
| Jul 1, 2026 | Monte Rosa Therapeutics Inc. | Other | +15,000 | — | — |
| Jul 1, 2026 | Monte Rosa Therapeutics Inc. | Other | −15,000 | — | — |
| Jun 19, 2026 | Black Diamond Therapeutics Inc. | Grant or award | +8,961 | $1.66 | $14,875 |
| Mar 20, 2026 | Black Diamond Therapeutics Inc. | Grant or award | +6,919 | $2.15 | $14,876 |
| Mar 10, 2026 | Korro Bio Inc. | Grant or award | +207,100 | $11.11 | $2,300,881 |
| Feb 9, 2026 | SpyGlass Pharma Inc. | Derivative conversion | +1,619,240 | — | — |
| Feb 9, 2026 | SpyGlass Pharma Inc. | Derivative conversion | +1,370,168 | — | — |
| Feb 9, 2026 | SpyGlass Pharma Inc. | Derivative conversion | +1,370,168 | — | — |
| Feb 9, 2026 | SpyGlass Pharma Inc. | Derivative conversion | +737,962 | — | — |
| Feb 9, 2026 | SpyGlass Pharma Inc. | Open-market purchase | +937,500 | $16.00 | $15,000,000 |
| Feb 9, 2026 | SpyGlass Pharma Inc. | Derivative conversion | +954,990 | — | — |
Questions about Ali Behbahani
What boards is Ali Behbahani on?
Ali Behbahani sits on the boards of Black Diamond Therapeutics Inc., CRISPR Therapeutics AG, CVRx Inc., Korro Bio Inc., Monte Rosa Therapeutics Inc., Nkarta Inc. and SpyGlass Pharma Inc.
How long has Ali Behbahani served on boards?
Our records show at least 21 years of board service across 7 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.